LOGIN  |  REGISTER
Viking Therapeutics
Recursion

ZimVie to Present at the 41st Annual J.P. Morgan Healthcare Conference

December 28, 2022 | Last Trade: US$12.00 0.55 -4.38

WESTMINSTER, Colo., Dec. 28, 2022 (GLOBE NEWSWIRE) -- ZimVie Inc. (Nasdaq: ZIMV), a global life sciences leader in the dental and spine markets, today announced that management will present at the 41st Annual J.P. Morgan Healthcare Conference in San Francisco, California.

Vafa Jamali, President and Chief Executive Officer, is scheduled to present on Wednesday, January 11, 2023, at 3:00 p.m. Pacific Time. Interested parties may access a live and archived version of the webcast of the presentation at: https://investor.zimvie.com/events-presentations/event-calendar.

About ZimVie

ZimVie is a global life sciences leader in the dental and spine markets that develops, manufactures, and delivers a comprehensive portfolio of products and solutions designed to treat a wide range of spine pathologies and support dental tooth replacement and restoration procedures. The company was founded in March 2022 as an independent, publicly traded spin-off of the Dental and Spine business units of Zimmer Biomet to breathe new life, dedicated energy, and strategic focus to its portfolio of trusted brands and products. From its headquarters in Westminster, Colorado, and additional facilities around the globe, the company serves customers in over 70 countries worldwide with a robust offering of dental and spine solutions including differentiated product platforms supported by extensive clinical evidence.
For more information about ZimVie, please visit us at www.ZimVie.com. Follow @ZimVie on Twitter, Facebook, LinkedIn, or Instagram.

Media Contact Information:

ZimVie
Laura Driscoll • This email address is being protected from spambots. You need JavaScript enabled to view it.
(774) 284-1606

Investor Contact Information:

Gilmartin Group LLC
Marissa Bych • This email address is being protected from spambots. You need JavaScript enabled to view it.

Terns Pharmaceuticals

Stock Quote

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

Featured Stock

C4 Therapeutics

C4 Therapeutics is pioneering a new class of small-molecule drugs that selectively destroy disease-causing proteins via degradation using the innate machinery of the cell. This targeted protein degradation approach offers advantages over traditional drugs, including the potential to treat a wider range of diseases...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page